PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.
How this was made
The 30-second read
Why it matters
Enrollment completion in the registrational Phase 2 monotherapy portion and a planned accelerated-approval NDA submission in Q1 2027 are the main near-term drivers. The cash balance and runway through Q2 2027 frame funding risk.
Market read
This is a company-specific biotech update combining clinical milestone progress, a concrete planned NDA timing, and updated liquidity runway.
What to watch
The NDA is planned, not filed yet; traders may focus on whether additional cohorts, endpoints, or CMC readiness could delay submission beyond Q1 2027.
Background
PMV Pharma is developing rezatapopt (PC14586), a p53 Y220C-targeted small molecule, in the PYNNACLE Phase 1/2 trial.
Ticker impact
PMV Pharmaceuticals says PYNNACLE Phase 2 monotherapy enrollment is complete and it plans an NDA for rezatapopt in Q1 2027.
Moderate upside bias on renewed biotech risk-on, with volatility tied to NDA readiness and subsequent FDA review milestones.
The article provides concrete development milestones (enrollment completion, planned NDA timing) plus updated cash runway, which can re-rate near-term probability of advancement.
Market effects
Adds incremental sentiment support for p53 reactivator and precision oncology small-cap development programs, though it is company-specific.
Limited, primarily US small-cap biotech investor focus.
Low, as the update is tied to US FDA designations and a US NDA timeline.
Counterpoint
Cash fell materially from year-end, so the market may discount the NDA timeline if burn rate accelerates or trial execution slips.
Key entities
- companyPMV Pharmaceuticals, Inc.
Nasdaq-listed precision oncology company developing rezatapopt for TP53 Y220C cancers.
- drug_candidateRezatapopt (PC14586)
p53 reactivator designed to bind the pocket in TP53 Y220C mutant protein.
- clinical_programPYNNACLE clinical trial
Phase 1/2 study evaluating rezatapopt in advanced solid tumors with TP53 Y220C mutation.
- regulatorFDA
Granted Fast Track designation and Orphan Drug Designation for rezatapopt in relevant indications.
